The markets remain full of fear fueled by unrelenting tariff talk. Each of the three major stock market averages came out of ...

Key Takeaways The S&P 500 and Nasdaq lost ground at midday as the Trump administration's reciprocal tariffs are set to kick ...

We recently published a list of Jim Cramer Discussed These 9 Stocks Recently. In this article, we are going to take a look at ...

The S&P 500 and the Nasdaq fell on Monday, with technology stocks leading declines, as investors steered clear of risk-laden ...

Stocks fell on Monday after the Wall Street Journal reported that President Donald Trump has pushed his team to be more ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

The S&P 500 and the Nasdaq hit more than six-month lows on Monday as investors steered clear of risk-laden assets on worries ...

Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian ...